Medically reviewed by Drugs.com. Last updated on Sep 17, 2020.
Applies to the following strengths: 5 mg/2 mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Nausea/Vomiting - Postoperative
Prophylaxis: 5 mg given IV infusion over 1 to 2 minutes ONCE
Treatment: 10 mg given via IV injection over 1 to 2 minutes) ONCE
-Preventative doses should be given at the induction of anesthesia.
-Treatment doses should be given after surgical procedures.
-IV lines may be flushed before or after administration with compatible fluids.
-Alone or in combination with an antiemetic of a different class for the prevention of PONV
-Treatment of postoperative nausea and vomiting (PONV) in patients who received antiemetic prophylaxis with an agent of a different class OR in those who did not receive prophylaxis
Renal Dose Adjustments
Mild to moderate renal dysfunction (estimated glomerular filtration rate [eGFR] 30 mL/min/1.73 m3 and greater): No adjustment recommended.
Severe renal dysfunction (eGFR less than 30 mL/min/1.73 m2): Not recommended.
Liver Dose Adjustments
Data not available
-Hypersensitivity to the active component or to any of the ingredients
Safety and efficacy have not been established in pediatric patients.
Consult WARNINGS section for additional precautions.
Data not available
-Oral formulations should be taken after meals.
-Oral solutions should be consumed with a liquid not containing alcohol.
-IV formulations should be inspected thoroughly for discoloration and particulate matter prior to administration; solutions that are discolored or with particulate matter should be discarded.
-IV: Protect from light and use within 12 hours of removing from protective carton.
-Oral solution: Store below 25; any unused solution should be discarded after 2 months of opening.
-Tablets: Protect from moisture.
-IV: Dilution is not required.
-Compatible: 5% dextrose, 0.9% sodium chloride, and water for injection
-Some oral solution and tablet formulations are not interchangeable. The manufacturer product information should be consulted.
-CARDIOVASCULAR: ECG monitoring in patients receiving IV formulations with/at risk of QT prolongation
-ENDOCRINE: Serum prolactin levels in patients receiving prolonged treatment
-HEMATOLOGIC: Hematologic investigations in patients receiving prolonged treatment with evidence/suspected of having blood dyscrasia
-HEPATIC: Signs/symptoms of liver toxicity should be immediately reported, especially in patients receiving prolonged treatment
-Inform patients that this drug may cause blurred vision, decreased reaction time, and/or somnolence, and they should avoid driving or operating machinery if these side effects occur.
-Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about amisulpride
- Side Effects
- During Pregnancy or Breastfeeding
- Drug Interactions
- En Español
- 4 Reviews
- Drug class: atypical antipsychotics
Other brands: Barhemsys